Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meena Subramanyam

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Pharmacology|June 18, 2011
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biologyXiao Hu, Larisa Miller, Sandra Richman, et al.
Annals of Neurology|August 26, 2010
Anti-JC virus antibodies: implications for PML risk stratificationLeonid Gorelik, Michaela Lerner, Sarah Bixler, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|September 15, 2010
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosisDarren P Baker, Robert Blake Pepinsky, Margot Brickelmaier, et al.
Neurology|September 17, 2017
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Kumar Kandadi Muralidharan, Geoffrey Kuesters, et al.
Nature Reviews. Drug Discovery|March 29, 2013
Challenges and approaches for the development of safer immunomodulatory biologicsJean G Sathish, Swaminathan Sethu, Marie-Christine Bielsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 6, 2013
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohortTomas Olsson, Anat Achiron, Lars Alfredsson, et al.
Bioanalysis|November 19, 2016
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity)Susan Richards, Lakshmi Amaravadi, Renuka Pillutla, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Pharmacology|June 18, 2011
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biologyXiao Hu, Larisa Miller, Sandra Richman, et al.
Annals of Neurology|August 26, 2010
Anti-JC virus antibodies: implications for PML risk stratificationLeonid Gorelik, Michaela Lerner, Sarah Bixler, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|September 15, 2010
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosisDarren P Baker, Robert Blake Pepinsky, Margot Brickelmaier, et al.
Neurology|September 17, 2017
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Kumar Kandadi Muralidharan, Geoffrey Kuesters, et al.
Nature Reviews. Drug Discovery|March 29, 2013
Challenges and approaches for the development of safer immunomodulatory biologicsJean G Sathish, Swaminathan Sethu, Marie-Christine Bielsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 6, 2013
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohortTomas Olsson, Anat Achiron, Lars Alfredsson, et al.
Bioanalysis|November 19, 2016
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 - LBA, biomarkers and immunogenicity)Susan Richards, Lakshmi Amaravadi, Renuka Pillutla, et al.
Pageof 4